Animal Models of Alzheimer's Disease

doi:10.3969/j.issn.1674-5817.2012.01.020

Abstract

Abstract: Alzheimer's disease (Alzheimer's disease, AD) is a neurodegenerative disease, its learning ability, behavioral and expression impairments exacerbate with age. AD animal models than simulate the AD disease's pathology are an essential tool to study this disease. A number of transgenic animal models had successfully established, including APPPS1, PS1/PS1, Tau protein transgenic mice and rapid aging-SAMP8 mice. Suitable animal model play an important role in the AD pathogenesis and drug development research. This article reviews the most common animal model of AD and its role in drug development.

Key words: Alzheimer's disease, Animal model, Transgenic

CLC Number:

LOK Keng-hoe, ZHAO Wen-juan, YING Ming. Animal Models of Alzheimer's Disease[J]. Laboratory Animal and Comparative Medicine, 2012, 32(1): 80-88.

References

[1] Bonardi C, de Pulford F, Jennings D, et al. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease[J]. Behav Brain Res, 2011,222(1):89-97.
[2] Citron M.Strategies for disease modification in Alzheimer's disease[J]. Nature Reviews Neuroscience, 2004, 5(9):677-685.
[3] 闵嵘, 盛树力, 赵志炜, 等. App17肽对app转基因小鼠aβ相关蛋白表达的影响[J]. 中国老年学杂志, 2008, 28(12):1045-1048.
[4] 吴云. Tau蛋白与阿尔茨海默病关系研究进展[J]. 中国健康月刊: B, 2011, 30(1):44-46.
[5] 苏怡汀, 李乐华. 阿尔茨海默病的神经生物学发病机制及相关治疗研究进展[J]. 医学临床研究, 2011,28(5):947-951.
[6] 秦红兵, 杨朝晔, 范忆江, 等. D-半乳糖诱导衰老小鼠模型的建立与评价[J]. 中国组织工程研究与临床康复, 2009, 13(7):1275-1278.
[7] 宋彩梅, 王红梅, 刘新民, 等. 肾虚型老年痴呆动物模型的建立[J]. 现代中西医结合杂志, 2011,20(22):2744-2748.
[8] 林海英, 吴春云, 于建云, 等. 学习记忆功能障碍与基底前脑胆碱能神经元改变的关系[J]. 泸州医学院学报, 2005, 28(5):385-387.
[9] 梁逸超, 崔玲玲, 王维. 铝与阿尔茨海默病的研究进展[J]. 医学综述, 2009, 15(16):2455-2458.
[10] 杨芳, 王双, 孙志伟. 阿尔茨海默病的免疫治疗策略及研究进展[J]. 生物技术通讯, 2009, 20(4):584-586.
[11] Walker JM, Fowler SW, Miller DK, et al.Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease[J]. Behav Brain Res, 2011,222(1):169-175.
[12] Bekris LM, Yu CE, Bird TD, et al.Genetics of Alzheimer disease[J]. J Geriatr Psychiatry Neurol, 2010, 23(4):213-227.
[13] Han X.The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease[J]. Molecular Neurobiology, 2010, 41(2):97-106.
[14] Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models[J]. Proc Natl Acad Sci U S A, 1999, 96(6):3228-3233.
[15] Minati L, Edginton T, Bruzzone MG, et al.Current concepts in Alzheimer's disease: a multidisciplinary review[J]. Am J Alzheimers Dis Other Demen, 2009, 24(2):95-121.
[16] Franberg J, Svensson AI, Winblad B, et al.Minor contribution of presenilin 2 for gamma-secretase activity in mouse embryonic fibroblasts and adult mouse brain[J]. Biochem Biophys Res Commun, 2011, 404(1):564-568.
[17] Fitzjohn SM, Kuenzi F, Morton RA, et al.A study of long-term potentiation in transgenic mice over-expressing mutant forms of both amyloid precursor protein and presenilin-1[J]. Mol Brain, 2010, 3(1):21.
[18] Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes[J]. Nat Med, 1998, 4(1):97-100.
[19] Hussain I.APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics[J]. CNS Neurol Disord Drug Targets, 2010, 9(4):395-402.
[20] Noble W, Hanger DP, Gallo JM.Transgenic mouse models of tauopathy in drug discovery[J]. CNS Neurol Disord Drug Targets, 2010, 9(4):403-428.
[21] Rovelet-Lecrux A, Hannequin D, Guillin O, et al.Frontotemporal dementia phenotype associated with MAPT gene duplication[J]. Journal of Alzheimer's Disease, 2010, 21(3):897-902.
[22] Nixon RA,Yuan A.Cytoskeleton of the Nervous System[M]. New York :Springer,2011.73-82.
[23] Santa Cruz KS PJ, Lewis J, Mariash A, et al. Cell loss and gliosis in a transgenic mouse with regulatable P301L tau overexpression[C]. In: Society for Neuroscience meeting. New Orleans, LA, 2003.
[24] Higuchi M, Maeda J, Ji B, et al.In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models[J]. Biochim Biophys Acta, 2010, 1802(4):373-388.
[25] Allen B, Ingram E, Takao M, et al.Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein[J]. J Neurosci, 2002, 22(21):9340-9351.
[26] Miyasaka T, Sato S, Tatebayashi Y, et al.Microtubule destruction induces tau liberation and its subsequent phosphorylation[J]. FEBS Lett, 2010, 584(14):3227-3232.
[27] Hutton M, Lewis J, Dickson D, et al.Analysis of tauopathies with transgenic mice[J]. Trends Mol Med, 2001, 7(10):467-470.
[28] Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein[J]. Nat Genet, 2000, 25(4):402-405.
[29] Lewis J, Dickson DW, Lin WL, et al.Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP[J]. Science, 2001,293(5534):1487-1491.
[30] Gang B, Yue C, Han N, et al.Limited hippocampal neurogenesis in SAMP8 mouse model of Alzheimer's disease[J]. Brain Res, 2011, 1389:183-193.
[31] Zhu L, Yu J, Shi Q, et al.Strain- and age-related alteration of proteins in the brain of SAMP8 and SAMR1 mice[J]. J Alzheimers Dis, 2011,23(4):641-654.
[32] Ma Q, Qiang J, Gu P, et al.Age-related autophagy alterations in the brain of senescence accelerated mouse prone 8 (SAMP8) mice[J]. Exp Gerontol, 2011, 46(7):533-541.
[33] Cui YJ, Huang MW, He YB, et al.Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model[J]. American Journal of Pathology, 2011, 178(3):1298-1308.
[34] Harris JA, Devidze N, Verret L, et al.Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network[J]. Neuron, 2010, 68(3):428-441.
[35] Cisse M, Halabisky B, Harris J, et al.Reversing EphB2 depletion rescues cognitive functions in Alzheimer model[J]. Nature, 2011, 469(7328):47-52.
[36] Butler D, Hwang J, Estick C, et al.Protective effects of positive lysosomal modulation in alzheimer's disease transgenic mouse models[J/OL]. PLoS One, 2011, 6(6):e20501.
[37] Medeiros R, Kitazawa M, Caccamo A, et al.Loss of muscarinic M1 receptor exacerbates alzheimer's disease-like pathology and cognitive decline[J]. The American journal of pathology, 2011, 179(2):980-991.
[38] Pereson S, Wils H, Kleinberger G, et al.Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models[J]. Journal of Pathology, 2009, 219(2):173-181.
[39] Ghosal K, Stathopoulos A, Pimplikar SW.APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation[J/OL]. PLoS One, 2010, 5(7):e11866.
[40] Ando K, Leroy K, Heraud C, et al.Accelerated Human Mutant Tau Aggregation by Knocking Out Murine Tau in a Transgenic Mouse Model[J]. American Journal of Pathology, 2011, 178(2):803-816.
[41] Takeuchi H, Iba M, Inoue H, et al. P301S mutant human Tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating[J]. PLoS One, 2011, 6(6):e21050.Epub.
[42] Fischer A, Sananbenesi F, Wang XY, et al.Recovery of learning and memory is associated with chromatin remodelling[J]. Nature, 2007, 447(7141):178-182.
[43] Zhu L, Yu JC, Shi QQ, et al.Strain- and age-related alteration of proteins in the brain of SAMP8 and SAMR1 mice[J]. Journal of Alzheimers Disease, 2011,23(4):641-654.
[44] John S, Thangapandian S, Sakkiah S, et al.Potent bace-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies[J]. BMC Bioinformatics, 2011, 12(Suppl 1):S28.
[45] Ooi CP, Loke SC, Yassin Z, et al. Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairment[J]. Cochrane Database Syst Rev, 2011, 4(CD007220.
[46] Lee KS, Divis PC, Zakaria SK, et al.Plasmodium knowlesi: Reservoir Hosts and Tracking the Emergence in Humans and Macaques[J]. PLoS Pathog, 2011, 7(4):e1002015.
[47] Yan Q, Zhang J, Liu H, et al.Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease[J]. J Neurosci, 2003, 23(20):7504-7509.
[48] Lleo A, Berezovska O, Herl L, et al.Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation[J]. Nat Med, 2004, 10(10):1065-1066.
[49] Citron M.Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge[J]. Trends Pharmacol Sci, 2004, 25(2):92-97.
[50] Gnjec A, Fonte JA, Atwood C, et al.Transition metal chelator therapy-a potential treatment for Alzheimer's disease?[J]. Front Biosci, 2002, 7:d1016-1023.
[51] Cherny RA, Atwood CS, Xilinas ME, et al.Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice[J]. Neuron, 2001, 30(3):665-676.
[52] Lee JY, Cole TB, Palmiter RD, et al.Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice[J]. Proc Natl Acad Sci USA, 2002, 99(11):7705-7710.
[53] Ritchie CW, Bush AI, Mackinnon A, et al.Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial[J]. Archives of Neurology, 2003, 60(12):1685-1691.
[54] Morgan D, Diamond DM, Gottschall PE, et al.A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease[J]. Nature, 2000, 408(6815):982-985.
[55] Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations[J]. J Neurosci, 2003, 23(34):10879-10883.
[56] Oddo S, Billings L, Kesslak JP, et al.Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome[J]. Neuron, 2004, 43(3):321-332.
[57] Cattepoel S, Hanenberg M, Kulic L, et al.Chronic Intranasal Treatment with an Anti-Aβ<sub>30-42</sub> scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease[J]. PLoS ONE, 2011, 6(4):e18296.
[58] Nicoll JA, Wilkinson D, Holmes C, et al.Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report[J]. Nat Med, 2003, 9(4):448-452.
[59] Hock C, Konietzko U, Streffer JR, et al.Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease[J]. Neuron, 2003, 38(4):547-554.
[60] Wang A, Das P, Switzer RC, et al.Robust amyloid clearance in a mouse model of alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy[J]. Journal of Neuroscience, 2011, 31(11):4124-4136.
[61] Marchesi VT.Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy[J]. Faseb Journal, 2011,25(1):5-13.
[62] Singh JCH, Alagarsamy V, Kumar SS, et al.Neurotransmitter metabolic enzymes and antioxidant status on Alzheimer's disease induced mice treated with Alpinia galanga (L.) Willd[J]. Phytotherapy Research, 2011,25(7):1061-1067.
[63] Budimir A.Metal ions, Alzheimer's disease and chelation therapy[J]. Acta Pharmaceutica, 2011, 61(1):1-14.
[64] Oehlrich D, Berthelot DJC, Gijsen HJM. gamma-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer's Drugs[J]. Journal of Medicinal Chemistry, 2011, 54(3):669-698.
[65] Vassar R.Alzheimer's therapy: a BACE in the hand?[J]. Nature Medicine, 2011, 17(8):932-933.
[66] Medina M, Avila J.Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease[J]. Current Pharmaceutical Design, 2010, 16(25):2790-2798.